Clinical nuclear medicine, vol.46, no.5, pp.415-418, 2021 (SCI-Expanded)
Prostate-specific membrane antigen (PSMA) overexpression in various tumors are demonstrated in both in vitro and in vivo studies. Prostate-specific membrane antigen-directed radionuclide therapies are generally used in prostate cancer and could be also useful in PSMA-avid other malignancies. Herein, we present a case of a 46-year-old male patient who had progressive metastatic testicular mixed germ cell tumor, despite repeated operations and treatments. Ga-68-PSMA PET/CT was performed to assess eligibility for Lu-177-PSMA therapy. Patient had intense PSMA uptake in metastatic lesions, and Lu-177-PSMA has been given to control of disease. However, alpha-fetoprotein level progressed, and mixed therapy response was detected in Ga-68-PSMA PET/CT.